...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Trial
2
Sep 18, 2016 10:00AM
3
Sep 18, 2016 02:59PM

Sep 19, 2016 10:17AM
3
Sep 19, 2016 11:25AM

Here is a good article that describes 3+3 trial designs. It seems that there are numerous variations on the theme and Zenith may even be using one of these instead of the basic 3+3 method.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684552/

masila

Share
New Message
Please login to post a reply